Advanced Glycation End Products: Do They Impair Bone Health in Diabetes?
- Authors: Papachristou, Stella; Rizzo, Manfredi; Papanas, Nikolaos
- Publication year: 2022
- Type: Nota o commento
- OA Link: http://hdl.handle.net/10447/584514
Abstract
In diabetes mellitus (DM), there is increased formation and accumulation of advanced glycation end products (AGEs), which represent a heterogeneous class of molecules produced by non-enzymatic glycation of various molecules during long-term hyperglycaemia. Several studies have examined the role of AGEs in DM complications. Accumulating evidence suggests that AGEs affect bone metabolism. New knowledge indicates that they may play a role in bone disease among DM subjects. More data are now needed to clarify their role and to explore new AGEs-based therapeutic options for optimal bone health in DM.